NDAORALSOLUTIONPriority Review
Approved
Sep 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
EMTRIVA (emtricitabine) by Gilead Sciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for hiv infection, hiv prevention, aids. First approved in 2005.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMTRIVA (emtricitabine) is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV replication by inhibiting the enzyme responsible for viral RNA conversion to DNA. It is indicated for HIV infection, HIV prevention (PrEP), hepatitis B, and AIDS management. The oral solution formulation enables flexible dosing across adult and pediatric populations.
$0.312MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with declining Part D claims signals contraction phase requiring defensive positioning and potential internal team restructuring.
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications (3)
Worked on EMTRIVA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.